On April 15, the Secretary of Commerce initiated an investigation to determine the effects on the national security of imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients, and key starting materials, and derivative products of those items. The Trade Alliance to Promote Prosperity submitted comments in response to the agency’s request…
Read MoreThe Trade Alliance to Promote Prosperity is calling on the Trump Administration to restore recently cancelled research funding that the Department of Health and Human Services (HHS) had committed to developing a bird flu (H5N1) vaccine for humans…
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., appeared on the nationally syndicated Alan Nathan show with guest host John Hayward from Breitbart News on May 14 to discuss President Trump's tariffs…
Read MoreThe Trade Alliance to Promote Prosperity and 23 Partner Organizations today delivered a letter to U.S. House Speaker Mike Johnson and U.S. Senate Majority Leader John Thune to express strong opposition to the potential inclusion of a "Most Favored Nation" (MFN) drug pricing model in the forthcoming budget reconciliation package…
Read MoreThe new U.S.-U.K trade deal offers a few good elements for the United States, but major problems remain, especially affecting innovative American big-tech companies like Amazon, Google, and Meta.
Read MoreThe Trade Alliance to Promote Prosperity (TAPP) today sent a letter, along with an issue guide, to members of the U.S. House Energy & Commerce Committee, urging them to oppose a "Most Favored Nation" (MFN) drug pricing model, even as President Trump is actively pushing them to impose an MFC model on prescription drugs covered by Medicaid.
Read MoreThe Trade Alliance to Promote Prosperity signed onto a coalition letter, initiated by the Center for a Free Economy, opposing limits on the ability of businesses to deduct state and local taxes paid, unless offset dollar for dollar by new, broad-based, and permanent pro-growth tax reforms…
Read MoreTomorrow is World Intellectual Property (IP) Day 2024—the annual celebration of intellectual property rights. TAPP recognizes the importance of American IP as it bolsters domestic innovation and is crucial to our global competitive standing.
Read MoreThe Trade Alliance to Promote Prosperity applauds a newly released report from the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee which highlights the need for 340B program reform.
Read MoreThe Trade Alliance to Promote Prosperity applauds President Trump’s Executive Order, issued on April 15, 2025, “Lowering Drug Prices by Once Again Putting Americans First,” for its call on Congress to eliminate the “pill penalty.”
Read MoreThe imposition of wide-ranging and heavy-handed tariffs that run contrary to Trade Alliance to Promote Prosperity (TAPP) principles notwithstanding, President Trump deserves credit for at least expressing the intention to provide exemptions to U.S. companies so they can compete internationally. This intent is consistent with sentiments expressed by the overwhelming majority of 1,000 American voters recently surveyed by Fabrizio Lee & Associates (the president’s own pollster) on behalf of TAPP…
Read MoreFor World Intellectual Property Day 2025 on April 26, the World Intellectual Property Organization (WIPO) has chosen the theme “IP and Music: Feel the Beat of IP.” At the Trade Alliance to Promote Prosperity, we are modifying WIPO’s theme to “Feel the (Heart) Beat of IP” in order to highlight the importance of Intellectual Property in medical innovation…
Read MoreTomorrow, the Senate Judiciary Committee is scheduled to be marking up several intellectual property bills that threaten to undermine intellectual property (IP) protections for innovators. American innovation, particularly in the biopharmaceutical industry, is vital to improving patient access to life-saving treatments and medications.
Read MoreThe Trade Alliance to Promote Prosperity today signed onto a coalition letter, initiated by the National Taxpayers Union, to the Speaker of the U.S. House of Representatives, Minority Leader of the U.S. House of Representatives, Majority Leader of the U.S. Senate, and Minority Leader of the U.S. Senate and copying the Secretary of the Treasury, Secretary of Commerce, and U.S. Trade Representative, warning that tariffs will harm American families and producers…
Read MoreThis morning, the America First Policy Institute (AFPI) published a new issue brief titled, Put Americans First by Ending Global Freeloading. In the brief, AFPI recommends the United States implement Most Favored Nation (MFN) drug policies in order to prevent the rest of the world from leeching off of American pharmaceutical innovation. While foreign countries freeloading off American innovation is a legitimate problem, simply importing foreign price controls into America’s healthcare system is not the answer…
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., appeared on the UpFront Show on KLTF radio on March 13 to discuss tariffs, free trade, companies masquerading as American, and the new poll that the organization recently commissioned through Fabrizio Lee & Associates…
Read MoreThe Trade Alliance to Promote Prosperity was referenced in a recent Real Clear Defense column, “Trump’s Tariffs – History Has Lessons To Be Followed,” by Gregory T. Kiley, former senior professional staff member, Senate Armed Services Committee; and U.S. Air Force Officer…
Read MoreThe Trade Alliance to Promote Prosperity was referenced in a recent Real Clear Policy column, “Conservatives Hope Trump Tariff Announcement Leverages Better Trade Deals,” by Peter Mihalick, a former legislative director and counsel to former Reps. Barbara Comstock of Virginia and Rodney Blum of Iowa…
Read MoreThe Trade Alliance to Promote Prosperity (TAPP) today released a national survey of 1,000 registered voters conducted for the organization from February 12-16, 2025, by Fabrizio Lee & Associates…
Read MoreCurrently, the Inflation Reduction Act enforces price controls on drugs under two different timelines. Small molecule drugs that are approved as New Drug Applications (NDAs) become eligible for price controls after nine years. Large molecule drugs, known as biologics, become eligible after 13 years. This unequal treatment is known as the “pill penalty.”…
Read More